The innovation in brief
VERIGRAFT makes it possible to use donated tissue that would otherwise go to waste. In this way the gift of donation is honored.
VERIGRAFT’s proprietary technology removes components that would be recognized as foreign by the patient’s immune system and replaces them by the patient’s own biological material.
Implantation to the patient
The personalized tissue is implanted to the patient. Personalization minimizes the risk of tissue rejection by the patient’s immune system.
The solution in 7 steps
VERIGRAFT focuses on four therapeutic areas; Veins, arteries, peripheral nerves and heart valves. The first clinical application is to treat Chronic Venous Insufficiency, CVI. VERIGRAFT’s lead product, the personalized tissue-engineered vein or P-TEVTM, is currently in clinical development.
VERIGRAFT’s revolutionary technology for personalized tissue has the potential to treat a wide range of indications. The development phase for the product candidates Personalized Tissue-Engineered Veins (P-TEVTM), Personalized Tissue-Engineered Arteries (P-TEATM), Personalized Tissue-Engineered Nerves (P-TENTM) and Personalized Tissue-Engineered Heart Valves (P-TEHVTM) currently range from pre-clinical to clinical development.
Product development for regenerative medicine